2BBBullish & Bearish
Esperion Therapeutics, Inc. (ESPR) trades on NASDAQ. It operates in the Health Care sector, Drug Manufacturers - Specialty & Generic industry. Its current 2BB score is 16 out of 100.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Esperion Therapeutics, Inc.’s current 2BB score is 16 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 12 | Very Low |
| Momentum | 29 | Weakening |
| Financial strength | 61 | Strong |
| Quality | 100 | Very Strong |
| Risk | 33 | Low |
| CEO | Sheldon Koenig |
| Founded | May 1998 |
| Employees | 294 |
| 52-week range | $1.00 – $4.18 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2026-11-04 | — | 0.0068 | — | $100.68M |
| 2026-08-03 | — | -0.001 | — | $94.28M |
| 2026-05-04 | — | -0.0159 | — | $96.13M |
| 2026-02-24 | — | 0.2642 | — | $182.20M |